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ABSTRACT
Objectives Sociodemographic and mental health 
characteristics are associated with contraceptive choices. 
We aimed to describe the sociodemographic, reproductive 
and mental health characteristics of all fertile- aged women 
in Finland who used hormonal contraception (HC) in 2017.
Design A nationwide, register- based study.
Setting All women living in Finland in 2017; data from 
the Care Register of Health Care, Medical Birth Register, 
Population Register Centre, Prescription Centre, Register of 
Induced Abortions.
Participants All women aged 15–49 with one redeemed 
HC prescription in 2017 (n=294 356), and a same- sized, 
age- matched and residence- matched, control group of 
non- users.
Outcomes Rates of HC use; associations between HC use 
and mental disorders, sociodemographic and reproductive 
characteristics.
Results 25.8% of women aged 15–49 years used HC. 
Women with the lowest socioeconomic levels had lower 
odds of using HC than women with upper- level statuses 
(OR, 95% CI students: 0.97, 0.94 to 0.99; entitled to 
pension: 0.66, 0.63 to 0.69; other: 0.87, 0.85 to 0.89; 
unknown: 0.90, 0.85 to 0.90). Women with the highest 
education (secondary: 1.46, 1.43 to 1.48; tertiary: 1.64, 
1.58 to 1.70; academic: 1.60, 1.56 to 1.63) and income 
(second quarter: 1.57, 1.54 to 1.60; third quarter: 1.85, 
1.82 to 1.89; fourth quarter: 2.01, 1.97 to 2.06), and 
unmarried women had higher odds of using HC than 
women with the lowest education and income levels, 
and married (0.61, 0.60 to 0.62), divorced (0.86, 0.84 to 
0.88), widowed (0.73, 0.65 to 0.83) or other marital status 
women (0.26, 0.22 to 0.30).
Parous women (0.70, 0.69 to 0.71), those with previous 
induced abortion(s) (0.91, 0.89 to 0.92) or recent eating 
(0.68, 0.62 to 0.75) or personality (0.89, 0.79 to 0.97) 
disorders had lower odds of HC use. Absolute risk 
differences between women with and without mental 
disorders ranged from 3.1% (anxiety disorders) to 10.1% 
(eating disorders).
Conclusions A quarter of the fertile- aged women use HC 
in Finland. Sociodemographic disparities persist in relation 
to HC use, although of small effect size. HC use is less 
common among women suffering from severe to moderate 
psychiatric disorders, especially eating disorders.
INTRODUCTION
Globally, a growing proportion of women 
has access to and uses contraception. While 
it is difficult to estimate the rates of use 
of less reliable methods, such as condoms 
and natural methods, figures based on sale 
records show that more than 40% of women 
aged 15–49 years used some type of hormonal 
contraception (HC) in the period 2010–2013 
in the Nordic countries. Oral contraceptive 
(OC) pills were the preferred method (used 
by more than 20% of the women), followed 
by the levonorgestrel- releasing intrauterine 
system (15%).1
Efficacy and availability of contraceptive 
methods, in addition to adequate policies of 
sexual and reproductive education and public 
health strategies, have resulted in a significant 
decline in the number of unwanted preg-
nancies and induced abortions in Finland, 
Strengths and limitations of this study
 ► Redeemed hormonal contraception (HC) prescrip-
tions are recorded in Finnish registers from 2017 
onwards, and this is the first study to examine these 
records for all women living in Finland.
 ► The studied population covers more than half of the 
female population of childbearing age in Finland.
 ► Register data with proven good validity and reliabili-
ty have been used in the study.
 ► Records of redeemed HC prescriptions do not report 
on the actual HC use. It was not possible to retrieve 
information on young women who obtained free 
contraception.
 ► We were not able to examine contraceptive use in 
women with less severe psychiatric conditions.
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especially among adolescents and young women. In 2015, 
Finland had the lowest abortion rate among the Nordic 
countries, with a decline from 19.7 per 1000 women in 
1973 to 8.2 in 2015. Similarly, the birth and abortion rates 
among adolescents aged 15–19 years declined from 10 
and 15 per 1000 women in 2000 to 6 and 8, respectively, 
in 2015.2 Thus, the benefits of contraceptive use seem 
to be related to reduced public health costs, improved 
women’s social and work functioning, as well as better 
physical and mental health.3
The Nordic countries traditionally have high rates 
of HC use. They are also among the countries with the 
highest levels of welfare and social equality, as well as 
easy access to healthcare services, including contracep-
tion. However, disparities in the use and types of contra-
ception continue to exist between and within countries 
worldwide. For example, sociodemographic and cultural 
factors, misconceptions and practical barriers, along 
with professionals’ knowledge and skills influence both 
the women’s attitude and choice, whether to use contra-
ception and which method, as well as the prescribers’ 
attitude and beliefs about contraceptive options.4–6 In 
addition, other factors that seem to be related to contra-
ceptive use and choices are mental disorders. Disorders 
such as depression and anxiety are related to unintended 
pregnancy and risky sexual behaviour.7 8 Other studies 
have reported that women with previous or ongoing 
psychological symptoms, mental disorders or impulsive or 
antisocial behaviours typically exhibit an inconsistent use 
of contraception.9–11 According to other studies, the risk 
of unintended pregnancy is also elevated in women with 
eating disorders.12 However, systematic data on their HC 
use are still lacking, and the subject needs to be further 
studied. On the other hand, recent studies have reported 
a possible higher risk for depressive disorder and suicidal 
behaviour among HC users, especially adolescents.13 14
Thus, given the recent availability (from 2017) of records 
of redeemed HC prescriptions in Finnish registers, we 
identified all women of childbearing age living in Finland 
and using HC in 2017, with the aim to better understand 
the pattern of use of HC, its underlying correlates, and its 
relationship to mental disorders (as indicated by a recent 
care episode for psychiatric disorders).
METHODS
Study population
Each individual living in Finland is given, at birth or 
immigration, a unique personal identification number. 
This number was used to select the groups of cases and 
controls for this study, and for the linkages between the 
different national registers. Cases were selected from the 
Prescription Centre, which is a centralised database for 
prescription data in the Kanta Services,15 and includes 
information on all prescribed and redeemed medica-
tions (including, from 2017, HC) of the population 
of Finland. Such information comprises the product 
Anatomical Therapeutic Chemical (ATC) code,16 date of 
prescription, prescribed amount in defined daily dose, 
number of prescribed packages, amount per package and 
date(s) of purchase.
All women living in Finland on 31 December 2017, 
with a record in the Prescription Centre of at least one 
redeemed prescription with ATC codes G02B (‘contra-
ceptives for topical use’), G03A (‘HC for systemic use’) 
or G03HB (‘antiandrogens and estrogens’) as of the year 
2017, were identified. Further, for each HC user, a control 
woman, matched by year of birth and municipality of resi-
dence, with no records of redeemed HC prescriptions 
in 2017, was randomly selected. Selection of the groups 
was performed by the Social Insurance Institution of 
Finland (SII) and by Statistics Finland. Of the original 
304 993 women with at least one redeemed HC prescrip-
tion in 2017, only those aged 15–49 years (n=294 445) 
were considered women of reproductive age,17 and were 
thus included. Since antiandrogen and oestrogen prepa-
rations, which are usually prescribed for reasons others 
than contraception, also exert a contraceptive effect, the 
18 281 women using ATC ‘G03HB’ preparations were 
included in the study. Because emergency contraception 
in Finland is available without prescription, the 89 women 
with a redeemed prescription with ATC code ‘G03AD’, 
and their matched controls, were excluded, resulting in a 
final population of 294 356 HC users (figure 1).
Sociodemographic characteristics
Information on sociodemographic characteristics of all 
the study participants on 31 December 2017 (age, munici-
pality of residence, civil status, family type, socioeconomic 
group, highest level of education, occupation and annual 
income) was obtained through Statistics Finland from the 
Population Register Centre, which includes basic infor-
mation of all Finnish citizens and foreign citizens perma-
nently residing in Finland.
Reproductive characteristics
Based on the Medical Birth Register, which includes 
data on all live births and stillbirths since 1987, and 
the Register of Induced Abortions, containing data on 
induced abortions in Finland since 1983, we defined 
the following reproductive factors: parity and number 
of delivered children at 31 December 2016; history and 
number of induced abortions before 2017; and recent-
ness of induced abortions (before 2016, 2016–2017 or no 
induced abortions).
Women who gave birth during 2017 were identified 
through the Medical Birth Register. Women who under-
went a sterilisation between 1987 and 2016 were identi-
fied through the Register of Sterilisations.
Mental health
Information on mental health was retrieved from the 
Care Register of Health Care, which includes data on 
inpatient care in hospitals, health centres, day surgeries 
and specialised outpatient care since 1994. Specifically, 
discharge diagnoses with International Classification of 
Diseases, 10th Revision codes F10–F19 (substance abuse), 
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F30–F39 (mood disorders), F40–F48 (anxiety disorders), 
F50 (eating disorders), F60 (personality disorders) and 
X60–X84 (intentional self- harm) in year 2016 were used 
to identify women with recent care episodes related to 
mental disorders.
Patient and public involvement
Patients and the public were not directly involved in the 
research process. Because this is a register- based study, no 
informed consent was needed.
Statistical analyses
We described the overall sample with respect to sociode-
mographic, reproductive and mental health characteristics 
using mean/median with SD/IQR and frequencies and 
percentages, respectively. The prevalence of HC use was 
explored across 70 regions as defined by Statistics Finland.18
We tested whether the odds of HC use differed by 
sociodemographic, reproductive and mental health char-
acteristics using univariable and progressively adjusted 
multivariable logistic regression models using the ‘gnm’ 
R- package,19 which allows for handling parameters of 
stratification factors with a large number of levels (in our 
case, ‘municipality of residence’). Moreover, given that 
the use and type of contraception,1 as well as the distri-
bution and prevalence of most of the studied predictors 
(eg, psychiatric disorders),20 21 and their reciprocal asso-
ciations, vary with age, we decided to additionally test the 
interaction between each predictor and age group.
Covariates in multivariable models for sociodemo-
graphic predictors consisted of all sociodemographic 
characteristics entered simultaneously, in addition to the 
age group. The interaction between each predictor and 
age group was tested in separate unadjusted models; if a 
significant interaction was found, age- stratified multivari-
able analyses were performed.
Multivariable models for reproductive and mental 
health predictors were progressively adjusted for age 
group, education and income level, and marital and 
socioeconomic status. A separate fully adjusted model 
further tested the interaction between age group and 
reproductive/mental health characteristics; if a signifi-
cant interaction was found, age- stratified multivariable 
analyses were performed.
In order to consider the groups of women with no need 
of HC, in sensitivity analyses, we excluded women who 
gave birth in 2017, and controlled for a history of sterili-
sation before 2017. Additionally, because contraception is 
commonly offered free- of- charge after an induced abortion, 
analyses were further controlled for a recent history (in 
2016–2017) of abortion. The progressive adjustments for 
covariates are described in online supplemental table 1.
For all the analyses, the two- tailed p values of <0.05 were 
considered statistically significant. All the analyses were 
performed with R software V.3.5.1.22
RESULTS
A total of 294 356 women aged 15–49 years (25.8% of the 
Finnish female population of that age range) were HC 
users. Their basic characteristics are reported in table 1. 
Their mean age was 28.9 years (SD 8.6); 24.0% were aged 
20–24 years and 6.2% aged 45–49 years. The regional 
distribution of HC use by age groups is illustrated in 
online supplemental figure 1.
Figure 1 Selection of the study population. ATC, anatomical therapeutic chemical; HC, hormonal contraception.
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Table 1 Basic characteristics of women who used HC in Finland in 2017
HC users (n=2 94 356) HC non- users (n=2 94 356)
Mean (SD)/n (%)/median (IQR range)
Age, years 28.9 (8.6) 28.9 (8.6)
Age group* % of the corresponding 
age population
  15–19 years 38 699 (13.2) 26.9 38 699 (13.2)
  20–24 years 70 524 (24.0) 44.2 70 524 (24.0)
  25–29 years 63 824 (21.7) 37.1 63 824 (21.7)
  30–34 years 44 220 (15.0) 25.9 44 220 (15.0)
  35–39 years 33 654 (11.4) 19.8 33 654 (11.4)
  40–44 years 25 181 (8.6) 15.6 25 181 (8.6)
  45–49 years 18 254 (6.2) 11.3 18 254 (6.2)
Family type
  Married couple with children 74 065 (25.2) 96 573 (32.8)
  Married couple without children 14 337 (4.9) 15 277 (5.2)
  Children with mother 30 100 (10.2) 31 689 (10.8)
  Children with father 2146 (0.7) 2346 (0.8)
  Cohabiting couple with common children 21 364 (7.3) 26 727 (9.1)
  Cohabiting couple with non- common children 5756 (2.0) 5213 (1.8)
  Cohabiting couple without children 65 559 (22.3) 36 898 (12.5)
  Other 141 (0.0) 842 (0.3)
  Missing/single 80 888 (27.5) 78 791 (26.8)
Marital status
  Unmarried 211 461 (71.8) 192 428 (65.4)
  Married 65 691 (22.3) 85 508 (29.1)
  Divorced 16 507 (5.6) 15 239 (5.2)
  Widowed/other 697 (0.2) 1181 (0.4)
Highest education level
  Upper secondary/postsecondary non- tertiary 142 340 (48.4) 134 095 (45.6)
  Short- cycle tertiary 8187 (2.8) 7229 (2.5)
  Academic degree (bachelor’s, master’s, doctoral 
or equivalent)
94 498 (32.2) 83 077 (28.2)
  Missing (including, eg, missing information on 
education other than of primary school level, 
school dropouts)
46 331 (16.8) 69 955 (23.8)
Occupation
  Employed 210 807 (71.6) 178 555 (60.7)
  Unemployed 17 681 (6.0) 23 559 (8.0)
  Student 50 519 (17.2) 59 973 (20.4)
  Entitled to pension 3629 (1.2) 6162 (2.1)
  Other 11 720 (4.0) 26 107 (8.9)
Socioeconomic group
  Self- employed 10 067 (3.4) 10 707 (3.6)
  Upper- level employees 37 170 (12.6) 34 810 (11.8)
  Lower- level employees 104 874 (35.6) 86 036 (29.2)
  Manual workers 45 113 (15.3) 42 254 (14.4)
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Sociodemographic characteristics
A greater proportion of unmarried or cohabiting women 
without children, compared with those of other marital 
statuses or family types, used HC. Additionally, a larger 
proportion of women with higher (upper secondary, 
tertiary or academic) compared with primary level educa-
tion; employed as upper- level or lower- level employees 
or manual workers compared with self- employed people, 
students, those entitled to pension or of other/unknown 
socioeconomic status; and those with higher annual 
income used HC (table 1).
Women with the lowest socioeconomic levels (students, 
pensioners, and other and unknown levels) had lower 
odds of using HC compared with women with upper- 
level statuses in a multivariable model simultaneously 
adjusting for all sociodemographic characteristics and 
age group. In the same model, women with the highest 
education and income levels and those who were not 
married had higher odds of using HC compared with 
women with the lowest education and income levels, and 
to those who were married, divorced, widowed or of other 
marital status (figure 2, online supplemental figure 2). 
The results did not change in sensitivity analyses.
The age group significantly interacted with socio-
economic and marital status, and education and 
income levels (p<0.0001). Specifically, in the younger 
age groups (15–29 years) the proportions of HC users 
were low among women entitled to pensions, but high 
among lower- level employees and manual workers. 
Additionally, the proportions of HC users were espe-
cially high among women with low/secondary and 
academic education in young adults (20–29 years). 
With increasing age, HC use increased among married 
and widowed women, but decreased among women in 
the lower income quarters (see online supplemental 
table 1).
Reproductive characteristics
Parous women were less likely to use contraception 
(OR 0.70, 95% CI 0.69 to 0.71, p<0.0001, in a model 
adjusted for age group, education, income and marital 
and socioeconomic status), and the odds for HC use 
decreased with the increasing number of children 
(ranging from OR 0.70, 95% CI 0.69 to 0.72 for one 
child; to OR 0.33, 95% CI 0.30 to 0.37, p<0.0001, for 
six or more children in the above- described adjusted 
HC users (n=2 94 356) HC non- users (n=2 94 356)
Mean (SD)/n (%)/median (IQR range)
  Pensioners 3741 (1.3) 6727 (2.3)
  Others 22 342 (7.6) 28 764 (9.8)
  Unknown 136 180 (4.6) 16 960 (5.8)
  Missing 848 (0.3) 4178 (1.4)
Income, € 19 582 (14 755) 17 042 (16 254)
Parous (before 2017) 89 674 (30.5) 106 415 (36.2)
No of delivered children before 2017
  0 204 682 (69.5) 187 941 (63.9)
  1 31 407 (10.7) 38 452 (13.1)
  2 39 504 (13.4) 42 478 (14.4)
  3–5 18 227 (6.2) 24 125 (8.2)
  ≥6 536 (0.2) 1360 (0.5)
Gave birth in 2017 9848 (3.4) 16 923 (5.8)
Induced abortions before 2017 35 189 (12.0) 37 853 (12.9)
Induced abortions before 2017, no
  0 259 167 (88.1) 256 503 (87.1)
  1 27 269 (9.3) 28 118 (9.6)
  2 5499 (1.9) 6652 (2.3)
  3 1648 (0.6) 2021 (0.7)
  ≥4 773 (0.3) 1062 (0.4)
Recent induced abortion(s) (in 2016–2017) 7493 (2.6) 4872 (1.7)
Sterilisation before 2017 930 (0.3) 5587 (1.9)
















pen: first published as 10.1136/bm





6 Toffol E, et al. BMJ Open 2020;10:e040072. doi:10.1136/bmjopen-2020-040072
Open access 
models). The proportion of HC users was especially 
low among young parous women (20–29 years: 37.8% 
vs 52.1% in non- parous women; p value for age×parity 
interaction <0.0001) (see online supplemental table 
2).
Women with a history of induced abortion(s) had 
slightly lower odds of HC use (OR 0.91, 95% CI 0.89 
to 0.92, p<0.0001, in a model adjusted for age group, 
marital and socioeconomic status, and education and 
income levels); the odds decreased with increasing 
number of abortions, ORs ranging from 0.94 (95% CI 
0.92 to 0.95) to 0.81 (95% CI 0.77 to 0.86, p<0.0001) 
for one to three or more abortions in the same fully 
adjusted model. The proportion of HC users was 
higher in teenagers and young women with a history 
of an induced abortion, while in the older age groups 
(35–49 years) it was lower among women with previous 
abortion(s) (p value for age×abortion interaction 
<0.0001) (see online supplemental table 2 and figure 
3). The results did not change after excluding women 
who gave birth in 2017. When examining the recent-
ness of abortion(s), the odds for using HC was higher 
Figure 2 Associations of HC use with sociodemographic characteristics in simple and multivariable conditional regression 
models. All sociodemographic characteristics (marital and socioeconomic status and education and income levels) are 
simultaneously entered in the adjusted model, in addition to the age group. HC, hormonal contraception.
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among women with a recent abortion (in 2016–2017) 
(OR 1.60, 95% CI 1.54 to 1.66, p<0.0001), but slightly 
lower among women with abortion(s) before 2016 (OR 
0.97, 95% CI 0.96 to 0.99, p=0.0021) compared with 
women with no such history in a fully adjusted model.
Mental health
The prevalence of care episodes due to psychiatric disor-
ders in 2016 is reported in table 2. Differences in absolute 
risks for not using HC between women with and without 
a recent psychiatric care episode ranged between 3.1% 
(anxiety disorders) and 10.1% (eating disorders), corre-
sponding to a difference in relative risks between 6.1% 
and 20.3%.
Most of the associations suggestive of lower HC use 
among women with mental disorders were lost after 
adjustment for covariates (marital and socioeconomic 
status, education and income levels and age group). The 
only exception was the lower odds for HC use in women 
suffering from eating and personality disorders, in both 
unadjusted (OR 0.66, 95% CI 0.60 to 0.73; and OR 0.69, 
95% CI 0.63 to 0.77, respectively) and fully adjusted 
models (OR 0.68, 95% CI 0.62 to 0.75; and OR 0.87; 
95% CI 0.79 to 0.97) (table 3).
We found a statistically significant interaction between 
age and a recent care episode due to manic episode/
bipolar disorder (p=0.0030), depressive episode, recur-
rent depressive disorder, anxiety disorders and person-
ality disorders (p<0.0001), substance abuse (p=0.014) and 
eating disorders (p=0.0087). The proportions of women 
using HC were higher among women suffering from 
substance abuse and anxiety disorders in the younger 
age category (15–19 years), but lower in almost all the 
other age groups. The prevalence of HC users among 
women with a recent care episode due to bipolar, eating 
or personality disorders, depressive episode or recurrent 
Table 2 Prevalence of recent care episodes for psychiatric 
disorders in women using and not using HC in Finland in 
2017
Psychiatric diagnosis




1030 (0.35) 1198 (0.41)
Depressive episode 4672 (1.59) 5291 (1.80)
Recurrent depressive 
disorder
2301 (0.78) 2721 (0.92)
Persistent mood disorder 278 (0.09) 319 (0.11)
Substance use 1045 (0.36) 1264 (0.43)
Anxiety disorders 6048 (2.06) 6817 (2.32)
Eating disorders 685 (0.23) 1032 (0.35)
Personality disorder 600 (0.21) 864 (0.29)
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depressive disorder, was especially lower than in healthy 
women in the younger (15–29 years) age groups, but 
higher in the middle- age groups (30–39 years) for bipolar 
and recurrent depressive disorder (figures 3 and 4, and 
online supplemental table 3).
In sensitivity analyses, the associations between lower 
HC use and a recent care episode for recurrent depres-
sive, personality or eating disorder remained in fully 
adjusted models (see online supplemental table 4). 
We found an interaction between the age group and a 
recent care episode for manic episode/bipolar disorder 
(p=0.0031), depressive episode and recurrent depressive 
disorder (p<0.0001), substance abuse (p=0.0086), anxiety 
disorders and personality disorders (p<0.0001) and 
eating disorders (p=0.024).
DISCUSSION
More than a quarter of the fertile- aged female population 
were using HC in Finland in 2017. HC users differed from 
non- users with respect to several sociodemographic and 
reproductive characteristics. Women with a recent care 
episode due to mental disorders tended to use HC less 
frequently than healthy women; specifically, HC use was 
especially low among women with a recent care episode 
for eating disorders and, to a lesser extent, personality 
disorders. However, all the observed differences were of 
small size, suggesting only a marginal relation to HC use.
The rate of HC use in Finland, as well as the propor-
tion of HC users among teenage girls (27%), are in line 
with those reported in other countries.23 24 The use of HC 
seemed to decline with age, with almost 60% of all HC 
users being younger than 30 years. This figure is likely to 
underestimate the real proportion of teenagers and/or 
students using HC in Finland, since an increasing number 
of municipalities provide young women (<25 years) with 
free contraception for a period ranging from 3 months 
to 1 year or longer, which is not captured by our study. A 
possible reason explaining the apparently low prevalence 
of HC use among older women is the increasing propor-
tion of women aged 30 years and over who opt for intra-
uterine contraception,1 which can be used for several 
years after insertion, and thus are not captured by our 
study.
In Finland, HC users appeared to have higher median 
income and education levels, and to belong to higher 
socioeconomic groups compared with non- users. Low 
Figure 3 Proportions of HC use among women with and 
without manic episode/bipolar disorder (A), depressive 
episode (B), recurrent depressive disorder (C) and anxiety 
disorder (D) diagnosis, by age group. P values for the 
interaction term are from fully adjusted conditional models 
(controlled for marital and socioeconomic status and 
education and income levels). HC, hormonal contraception.
Figure 4 Proportions of HC use among women with and 
without eating disorders (A), substance abuse (B) and 
personality disorder (C) diagnosis, by age group. P values 
for the interaction term are from fully adjusted conditional 
models (controlled for marital and socioeconomic status and 
education and income levels). HC, hormonal contraception.
copyright.
 on O











pen: first published as 10.1136/bm





9Toffol E, et al. BMJ Open 2020;10:e040072. doi:10.1136/bmjopen-2020-040072
Open access
education and income levels, as well as low occupational 
rate and lower socioeconomic status, are well- recognised 
indicators of non- use and inconsistent use of HC, as well 
as of use of less effective contraceptive methods, such 
as condoms.25–28 There are probably several reasons for 
this pattern, such as difficulties in accessing healthcare 
services, unemployment or instable family relations. 
On the other hand, the reverse association, that is, that 
non- use of contraception could lead to poorer educa-
tional attainment and lower income due to a higher risk 
of unintended pregnancy, is likewise plausible. Partly in 
line with previous studies,28 29 we found that married and 
parous women were less likely to use HC, and the asso-
ciation became stronger with the increasing number of 
children. Again, the use of long- acting reversible contra-
ceptive methods may explain these figures. However, the 
small size of the observed differences suggests that all 
these factors have a fairly modest effect. In addition, the 
overall rate of contraceptive use in Finland, as well as the 
proportions of HC users among the most disadvantaged 
groups (eg, women with missing/primary education or 
belonging to the lower socioeconomic groups) were still 
rather high. Interestingly, we found that women with a 
recent abortion, and especially those who belong to the 
young age group, were more likely to use HC. This is an 
encouraging finding, as it suggests that successful poli-
cies, postabortion care and contraception provision may 
have been implemented.30
Mental disorders such as depressive, substance abuse 
and anxiety disorders have been associated with poor 
contraceptive compliance, inconsistent use or non- use 
of contraception and use of less- effective and more user- 
dependent methods.8 31 32 Our study confirmed that the 
odds of HC use are lower among women with a recent 
care episode for mental disorders. People suffering from 
psychiatric morbidity have an elevated risk for engaging 
in risky sexual behaviour,33 for unintended pregnancy,7 34 
and having an induced abortion. A survey on outpatients 
with mental disorders reported that more than a quarter 
of the sexually active women did not use contracep-
tion and 61% of pregnancies were unintended.35 In a 
sample of low- income women referred to family plan-
ning services, women with symptoms of depression, espe-
cially if comorbid with alcohol abuse, were more likely to 
choose less- effective methods or no method at all rather 
than hormonal methods.36 In women aged 18–20 years, 
depressive, anxiety or stress symptoms were associated 
with further non- use of contraception or use of less- 
effective, user- dependent methods,8 as well as with lower 
proportions of consistent contraception use.37 The rate 
of unintended pregnancy was higher among women with 
stress symptoms, as well as among women with perceived 
moderate/high social discrimination.38 39 In our study, 
age seemed to add to the associations between mental 
disorders and HC use. Indeed, teenage women with a 
recent care episode for anxiety disorders or substance 
abuse were using HC more often than their counterparts. 
However, this tendency reversed after 20 years of age. On 
the one hand, this suggests that effective psychiatric and 
reproductive counselling are available for teenage girls, 
possibly through student welfare services. The finding 
might also reflect successful reproductive education in 
high schools. Further, we speculate that young women, 
especially those suffering from a mental disorder, are 
lacking easily accessible and long- lasting mental and 
reproductive support after high school. However, these 
results have to be taken with caution. For example, the 
health service access/user bias could explain at least part 
of the findings. Indeed, women with a diagnosed mental 
condition are more likely to use healthcare services and 
become HC users. Similarly, HC users are more likely to 
use healthcare services and have their mental disorders 
diagnosed. On the other hand, the possibility that HC 
use may be related, in a subgroup of susceptible women, 
to higher vulnerability to psychiatric disorders cannot be 
totally ruled out. However, the effect sizes were modest, 
with an absolute difference ranging between 3% and 
10%, which suggests that psychiatric conditions are only 
marginally related to contraceptive use among Finnish 
women of childbearing age. Rather, it is plausible that a 
combination of sociodemographic- related, reproductive- 
related and mental health- related factors reciprocally 
contribute to women’s contraceptive choice.
A novel finding of our study is the clearly low rate of 
HC use among women suffering from eating disorders. 
Women with eating disorders commonly have menstrual 
abnormalities, and may assume they are not fertile. Even 
if these women often have reduced fertility, they are also 
at higher risks of unplanned pregnancy and induced 
abortion compared with those with no (active) eating or 
other psychiatric conditions,12 40–43 possibly due to non- 
use of contraception.
Our findings have public health implications. Although 
Finland is a country with high levels of welfare and social 
equalities, socioeconomic health inequalities do exist.44 
Our study confirms this and calls for the implementation 
of strategies aimed to reduce barriers in access to contra-
ception. Education regarding reproduction and contra-
ception starting from primary school, easy access to family 
planning services for all women and couples, and refining 
national policies on uniform access to free contraception 
are some of the strategies that are being implemented. 
Our results point to unmet reproductive needs of women 
belonging to high- risk groups, such as young women with 
mental disorders, especially eating disorders. To date, no 
study has examined in detail HC use and consistency of 
use among these women, which highlights the impor-
tance of promoting reproductive care and contraception 
use among young women with these disorders. This might 
be done for example by strengthening the collaboration 
between reproductive and mental health professionals.
There are some limitations to the present study. First, 
a record of a redeemed HC prescription does not guar-
antee its actual use. However, because HC is not reim-
bursed by the SII, it is likely that the majority of those who 
purchased the drug did in fact use it. By using register 
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data on redeemed prescriptions rather than medical 
records of prescriptions, we were able to exclude primary 
non- compliance. Second, we were not able to identify 
women who had an intrauterine device inserted in 2017 
but was removed or expelled soon after insertion. Simi-
larly, we cannot exclude that a number of women in the 
control group were in fact using HC, for example because 
of prescriptions redeemed, or intrauterine devices or 
implants inserted during the previous years but were 
still in use in 2017. However, we were able to include 
in the HC user group women who had a prescription 
made before, but who redeemed it in 2017. Because the 
limitation relative to the HC- users and non- users defini-
tion similarly applies to both groups, it is likely that the 
introduced bias is minimal. Although pharmacy data and 
prescription registers are accurate and complete,45 the 
completeness of the present data cannot be guaranteed, 
because the HC records were included in the Prescrip-
tion Centre only recently. Further, it was not possible to 
retrieve information on the real purchase of contracep-
tive methods that do not require a prescription or on 
young women who obtained free contraception as part 
of municipal programmes. Because data on secondary 
and tertiary healthcare before 2016 were not available, 
women with no need of HC due to history of hysterec-
tomy could not be accounted for in the sensitivity anal-
yses. Another limitation arises from the definition of 
mental disorders that are based on hospital or outpatient 
clinic discharge diagnoses in 2016, and as such capture 
only recent moderate to severe disorders. Thus, we were 
not able to examine contraceptive use in relation to less 
severe and rather prevalent psychiatric conditions. Addi-
tionally, because of the cross- sectional design of the study, 
it was not possible to test any hypotheses on the causality 
of the associations between HC use and mental disorders. 
Moreover, because parity was defined on the basis of deliv-
ered children as recorded in the Medical Birth Register 
since 1987, information for the oldest members of our 
cohorts (born in 1968) may be incomplete. However, this 
limitation likely concerns only a small number of births/
women.
Despite the above limitations, strengths of the study 
include the representativeness of the population, 
covering more than half of the female population of 
childbearing age, and the use of register data with proven 
good validity and reliability.46 By using uniform criteria 
across the whole study population to identify HC users, 
we were able to reduce the potential for information bias. 
Further, the possibility of interlinking multiple social and 
healthcare registers guaranteed extensive, valid and reli-
able information of the study population.
CONCLUSIONS
In Finland more than 25% of fertile- aged women use HC 
(either OC or contraceptives for topical use). Sociodemo-
graphic and health disparities still exist in relation to HC 
use, although the size of their effect is rather small. New 
public health strategies should promote access to effec-
tive contraception among more disadvantaged women 
and those with moderate to severe mental disorders, 
including eating disorders.
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